Egetis Therapeutics AB (SE:EGTX)
FRANKFURT:EGTX
Top Page
Egetis Therapeutics AB
(Frankfurt:EGTX)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr6.00
Action:N/ADate:03/17/26
The score is held back primarily by weak financial performance (large losses and persistent cash burn), which outweighs modest balance-sheet leverage. Technical signals are comparatively constructive with price above key moving averages and positive MACD, while valuation remains challenged due to negative earnings and no dividend data.
Positive Factors
Orphan-disease focus
A clear strategic focus on orphan and rare-disease indications creates durable structural benefits: smaller, faster clinical trials, regulatory incentives and potential premium pricing. This specialization can sustain differentiated market positioning and higher long-term per-patient economics if programs succeed.
Negative Factors
Severe cash burn
Material negative operating and free cash flow are structural headwinds for a biotech focused on development stage programs. Persistent cash burn compels frequent financing, increases dilution risk, and can force reprioritization or delay of programs, undermining long-term execution and strategic optionality.
Read all positive and negative factors
Positive Factors
Negative Factors
Orphan-disease focus
A clear strategic focus on orphan and rare-disease indications creates durable structural benefits: smaller, faster clinical trials, regulatory incentives and potential premium pricing. This specialization can sustain differentiated market positioning and higher long-term per-patient economics if programs succeed.
Read all positive factors
Egetis Therapeutics AB (EGTX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.37B
Dividend YieldN/A
Average Volume (3M)792.52K
Price to Earnings (P/E)―
Beta (1Y)-0.24
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees38
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding395,162,660
10 Day Avg. Volume1,042,665
30 Day Avg. Volume792,519
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Egetis Therapeutics AB Business Overview & Revenue Model
Company Description
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline inc...
How the Company Makes Money
null...
Egetis Therapeutics AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 62.40M | 46.10M | 57.60M | 22.50M | 38.24M |
| Gross Profit | 12.40M | 34.50M | -146.90M | -120.10M | -58.28M |
| EBITDA | -346.90M | -317.40M | -319.10M | -191.00M | -101.90M |
| Net Income | -342.50M | -343.60M | -326.90M | -189.50M | -104.73M |
Balance Sheet | |||||
| Total Assets | 639.10M | 792.30M | 760.20M | 561.10M | 569.27M |
| Cash, Cash Equivalents and Short-Term Investments | 215.80M | 351.00M | 303.30M | 127.70M | 143.97M |
| Total Debt | 76.50M | 117.40M | 113.00M | 2.70M | 4.20M |
| Total Liabilities | 300.40M | 299.40M | 214.60M | 54.90M | 42.23M |
| Stockholders Equity | 338.70M | 492.80M | 545.60M | 506.20M | 527.04M |
Cash Flow | |||||
| Free Cash Flow | -268.60M | -227.90M | -278.40M | -173.50M | -130.28M |
| Operating Cash Flow | -267.10M | -227.90M | -278.40M | -173.50M | -130.11M |
| Investing Cash Flow | -2.80M | -1.20M | -100.00K | -1.70M | -5.96M |
| Financing Cash Flow | 140.00M | 270.90M | 458.90M | 155.70M | -8.90M |
Egetis Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Egetis Therapeutics AB Corporate Events
Egetis Strengthens Rare Disease Push With New Chief Medical Officer
Apr 9, 2026
Egetis Therapeutics has appointed Tiago Nunes as Chief Medical Officer, effective May 1, 2026, bringing in a seasoned clinical development leader with a strong track record in advancing rare disease therapies through approval and launch, including...
Egetis Wins Conditional FDA Name Nod for Emcitate Ahead of Priority Review
Apr 8, 2026
Egetis Therapeutics has received conditional acceptance from the U.S. Food and Drug Administration for Emcitate as the proprietary name of its tiratricol-based treatment for MCT8 deficiency, with final approval tied to the outcome of the ongoing n...
Egetis Wins FDA Priority Review for First Potential U.S. Treatment for MCT8 Deficiency
Mar 27, 2026
Egetis Therapeutics has announced that the U.S. Food and Drug Administration has accepted and validated its New Drug Application for Emcitate, or tiratricol, for the treatment of MCT8 deficiency. The filing has been granted Priority Review, with a...
Egetis Therapeutics Highlights Rare Disease Focus and Commercialization Plans in 2025 Annual Report
Mar 24, 2026
Egetis Therapeutics’ 2025 annual report outlines its progress and strategic focus in rare disease therapies, highlighting Emcitate for MCT8 deficiency and Aladote as key assets. The report emphasizes commercialization plans in Europe and lau...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.